Literature DB >> 16819511

STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.

S R Walker1, E A Nelson, D A Frank.   

Abstract

Deregulated expression of BCL6 is a pathogenic event in many lymphomas. BCL6 blocks cellular differentiation by repressing transcription of its target genes, and this may promote tumorigenesis. Conversely, the transcription factor signal transducers and activators of transcription (STAT)5 promotes differentiation in many systems. STAT5 upregulates a number of genes repressed by BCL6, raising the possibility that STAT5 and BCL6 have opposing roles in transcriptional regulation. Therefore, we sought to determine the effects of STAT5 activation on BCL6 expression and function. We found that activation of STAT5 downregulates BCL6 expression in B-lymphoma cells and other hematopoietic cell lines. We identified two potential STAT-binding regions in the first exon and first intron of BCL6 that fell within regions of high inter-species homology, suggesting conservation of regulatory function. STAT5 can bind inducibly and regulate transcription at one of these regions, identifying BCL6 as a STAT5 target gene. Additionally, STAT5-mediated downregulation of BCL6 results in loss of BCL6 repression of its target genes, confirming that STAT5 is a negative regulator of BCL6 function. The STAT5 responsive region of the BCL6 gene is mutated frequently in B-cell lymphomas, suggesting that loss of the repressive effects of STAT5 on BCL6 might contribute to the pathogenesis of these cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16819511     DOI: 10.1038/sj.onc.1209775

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  66 in total

1.  Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells.

Authors:  Feng Fang; Jiamao Zheng; Traci L Galbaugh; Alyson A Fiorillo; Elizabeth E Hjort; Xianke Zeng; Charles V Clevenger
Journal:  J Mol Endocrinol       Date:  2010-03-17       Impact factor: 5.098

Review 2.  Erythropoietin receptor response circuits.

Authors:  Don M Wojchowski; Pradeep Sathyanarayana; Arvind Dev
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

Review 3.  B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.

Authors:  Weimin Ci; Jose M Polo; Ari Melnick
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

4.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.

Authors:  Leandro C Cerchietti; Katerina Hatzi; Eloisi Caldas-Lopes; Shao Ning Yang; Maria E Figueroa; Ryan D Morin; Martin Hirst; Lourdes Mendez; Rita Shaknovich; Philip A Cole; Kapil Bhalla; Randy D Gascoyne; Marco Marra; Gabriela Chiosis; Ari Melnick
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

5.  Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.

Authors:  Suhu Liu; Sarah R Walker; Erik A Nelson; Robert Cerulli; Michael Xiang; Patricia A Toniolo; Jun Qi; Richard M Stone; Martha Wadleigh; James E Bradner; David A Frank
Journal:  Mol Cancer Ther       Date:  2014-01-16       Impact factor: 6.261

6.  BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.

Authors:  Jie Ding; Wilhelm G Dirks; Stefan Ehrentraut; Robert Geffers; Roderick A F MacLeod; Stefan Nagel; Claudia Pommerenke; Julia Romani; Michaela Scherr; Lea A I Vaas; Margarete Zaborski; Hans G Drexler; Hilmar Quentmeier
Journal:  Haematologica       Date:  2015-03-13       Impact factor: 9.941

Review 7.  Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.

Authors:  André Ballesteros-Tato
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

Review 8.  Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.

Authors:  Samir Parekh; Gilbert Privé; Ari Melnick
Journal:  Leuk Lymphoma       Date:  2008-05

Review 9.  Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer.

Authors:  Sarah R Walker; Michael Xiang; David A Frank
Journal:  Mol Cell Endocrinol       Date:  2013-03-24       Impact factor: 4.102

10.  Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Authors:  Erik A Nelson; Sarah R Walker; Alicia Kepich; Laurie B Gashin; Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Kenneth C Anderson; David A Frank
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.